PNC Financial Services Group’s Terns Pharmaceuticals TERN Stock Holding History

PNC Financial Services Group’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,060	Closed	-$109K	–	5346
2026 Q1	$109K	Buy	2,060 +1,124	+120%	+$46.2K	﹤0.01%	2757
2025 Q4	$37.8K	Sell	936 -147	-14%	-$3.4K	﹤0.01%	3363
2025 Q3	$8.13K	Buy	1,083 +304	+39%	+$1.94K	﹤0.01%	4017
2025 Q2	$2.91K	Buy	779 +296	+61%	+$924	﹤0.01%	4303
2025 Q1	$1.33K	Buy	+483	New	+$1.97K	﹤0.01%	4458
2024 Q2	–	Sell	-17	Closed	-$112	–	4916
2024 Q1	$112	Buy	17 +9	+113%	+$59	﹤0.01%	4644
2023 Q4	$52	Buy	+8	New	+$42	﹤0.01%	4560

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

PNC Financial Services Group's TERN Position: Q2 2026 in Review

PNC Financial Services Group sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 2,060 shares — an estimated $109K sold.

PNC Financial Services Group first reported a position in TERN in Q4 2023 and held it in 7 quarters. The position peaked at $109K in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

PNC Financial Services Group reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
PNC Financial Services Group sold 2,060 Terns Pharmaceuticals shares in Q2 2026, an estimated $109K.
PNC Financial Services Group first reported a position in Terns Pharmaceuticals in Q4 2023 and held it in 7 quarters.
PNC Financial Services Group's Terns Pharmaceuticals position peaked at $109K in Q1 2026.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.